These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17378699)

  • 21. Geography and destiny: local-market perspectives on developing Medicare Advantage regional plans.
    Hurley RE; Strunk BC; Grossman JM
    Health Aff (Millwood); 2005; 24(4):1014-21. PubMed ID: 16012141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Medicare Part D drug benefit: lessons from the experience with drug discount cards.
    Doering PL
    Am J Geriatr Cardiol; 2005; 14(6):308-12. PubMed ID: 16276128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Through the looking glass: the politics of the Medicare Prescription Drug, Improvement, and Modernization Act.
    Oberlander J
    J Health Polit Policy Law; 2007 Apr; 32(2):187-219. PubMed ID: 17463405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Explosion in the medicine chest.
    Zarabozo C
    Health Care Financ Rev; 1999; 20(3):1-13. PubMed ID: 10558014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Agency for Healthcare Research and Quality's children's health research portfolio.
    Schultz D; Seid M; Stoto MA; Burstain JM
    Matern Child Health J; 2010 Jan; 14(1):1-8. PubMed ID: 19011958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. United States pharmacopeia development of the Medicare model formulary guidelines.
    Bielory L;
    Am J Geriatr Cardiol; 2005; 14(6):301-7. PubMed ID: 16276127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medicare and state health care programs; fraud and abuse: OIG civil money penalties under the Medicare prescription drug discount card program. Interim final rule with comment period.
    Office of Inspector General (OIG), HHS
    Fed Regist; 2004 May; 69(97):28842-6. PubMed ID: 15151115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the Medicare Prescription Drug Improvement and Modernization Act on the management of colorectal cancer.
    Siegel J
    Am J Health Syst Pharm; 2006 May; 63(9 Suppl 2):S18-21. PubMed ID: 16641253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medicare program; identification of backward compatible version of adopted standard for e-prescribing and the Medicare prescription drug program (version 8.1). Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2006 Jun; 71(121):36020-4. PubMed ID: 16795952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in reimbursement rates and rules associated with the Medicare Prescription Drug Improvement and Modernization Act. Introduction.
    Johnson PE
    Am J Health Syst Pharm; 2006 Nov; 63(21 Suppl 7):S2-6. PubMed ID: 17057057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medicare Part D: an overview of its practical and clinical impact.
    Usdin S
    Am J Geriatr Cardiol; 2005; 14(6):284-8; quiz 289-90. PubMed ID: 16276124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medicare program: Medicare Advantage and Prescription Drug Benefit programs: final marketing provisions. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2008 Sep; 73(182):54207-23. PubMed ID: 18985950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Medicare Prescription Drug Improvement and Modernization Act of 2003: summary analysis and preliminary assessment of implications for radiology.
    Moran DW
    J Am Coll Radiol; 2004 May; 1(5):322-30. PubMed ID: 17411596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of comparative effectiveness research on interventional pain management: evolution from Medicare Modernization Act to Patient Protection and Affordable Care Act and the Patient-Centered Outcomes Research Institute.
    Manchikanti L; Falco FJ; Benyamin RM; Helm S; Parr AT; Hirsch JA
    Pain Physician; 2011; 14(3):E249-82. PubMed ID: 21587337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacist and the Medicare Modernization Act: beauty and the beast?
    Hutchison LC
    Consult Pharm; 2007 Jan; 22(1):57-9. PubMed ID: 17367253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementing the Medicare part D prescription drug benefit program: implications for public health policy and practice.
    Rosenbaum S; Teitelbaum J
    Public Health Rep; 2005; 120(4):467-9. PubMed ID: 16025728
    [No Abstract]   [Full Text] [Related]  

  • 38. Medicare prescription drugs: making the new program work.
    Jaffe J
    EBRI Issue Brief; 2004 Jun; (270):1-14. PubMed ID: 15218820
    [No Abstract]   [Full Text] [Related]  

  • 39. How beneficiaries fare under the new Medicare drug bill.
    Moon M
    Issue Brief (Commonw Fund); 2004 Jun; (730):1-16. PubMed ID: 15176395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What will the new medicare drug benefit mean for Minnesota physicians?
    Liebow M
    Minn Med; 2005 Mar; 88(3):38-41. PubMed ID: 15852596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.